Federal Circuit Reverses in Barry v. DePuy Spinal Patent Dispute

Introduction

In a significant development for medical device patent litigation, the U.S. Court of Appeals for the Federal Circuit reversed and remanded the lower court’s decision in Mark A. Barry v. DePuy (Case No. 23-2234), concluding proceedings on January 20, 2026, after nearly 901 days of litigation. The case centered on five patents covering spinal derotation and minimally invasive surgery (MIS) correction technology, with DePuy’s EXPEDIUM® Vertebral Derotation System and VIPER® 3D MIS Correction Set named as the accused products.

For patent attorneys, IP professionals, and medical device R&D teams, this reversal carries meaningful implications. A “reversed and remanded” outcome signals that the appellate court identified a fundamental legal error below — whether in claim construction, infringement analysis, or procedural application — demanding fresh consideration. In the competitive spinal implant and surgical instrumentation market, where patent portfolios define market exclusivity, understanding why the Federal Circuit intervened is critical intelligence.

Case Overview

The Parties

Patents at Issue

This landmark case involved five U.S. patents covering spinal vertebral derotation methods and surgical correction systems — technologies central to minimally invasive spine surgery. The breadth of this five-patent portfolio across multiple continuation applications reflects a prosecution strategy designed to create layered, overlapping protection across the underlying inventive concepts.

• • US9668788B2 — Spinal derotation system
• • US7670358B2 — Vertebral derotation method
• • US9339301B2 — MIS correction technology
• • US9668787B2 — Spinal correction system
• • US8361121B2 — Spinal derotation methods

Litigation Timeline & Procedural History

The case was filed on August 3, 2023, before the Court of Appeals for the Federal Circuit — the exclusive appellate forum for U.S. patent cases — indicating this appeal followed a prior district court proceeding. The 901-day duration from filing to closure reflects the typical pace of Federal Circuit appellate patent matters, which involve extensive briefing schedules, oral argument, and deliberation periods.

The appeal arose from a patent infringement action, with the Federal Circuit ultimately issuing its “Reversed and Remanded” order on January 20, 2026. The specific district court below and its original ruling details were not disclosed in available case records, but the reversal mandates that the lower tribunal reconsider the matter consistent with the Federal Circuit’s guidance.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a Reversed and Remanded judgment — the court did not affirm the lower tribunal’s decision but instead found reversible legal error and returned the case for further proceedings. No damages amount was disclosed in available records. No information regarding injunctive relief was provided in the case data.

What “Reversed and Remanded” Means in Patent Appeals

A reversal at the Federal Circuit is not a routine outcome. It signifies that the appellate panel identified one or more legal errors material enough to change the result below. In patent infringement appeals, reversals most commonly arise from:

• Erroneous claim construction — the lower court interpreted patent claim language too narrowly or too broadly, affecting the infringement or validity analysis
• Improper summary judgment — the lower court resolved disputed factual issues that should have proceeded to trial
• Legal error in applying infringement standards — e.g., incorrect application of the doctrine of equivalents or means-plus-function analysis
• Validity determination errors — incorrect obviousness or anticipation rulings

Given that this case involved five separate patents across a family of continuation applications with overlapping claim structures, claim construction complexity was likely significant. Spinal surgery method patents — particularly those covering vertebral derotation sequences — often turn on precise claim language that courts must construe carefully. A misreading of terms like “derotating,” “correcting,” or structural claim limitations could fundamentally alter the infringement analysis for both the EXPEDIUM® and VIPER® platforms.

Legal Significance

The Federal Circuit’s reversal preserves and potentially strengthens the plaintiff’s infringement position, sending the case back for a reconsidered determination. For the broader medical device patent community, this outcome reinforces several important principles:

1. Claim construction is the linchpin. In multi-patent portfolios built on continuation families, the Federal Circuit applies de novo review to claim construction — meaning no deference to the lower court. Parties should draft and litigate claim construction positions with appellate scrutiny in mind from the outset.
2. Individual inventor patents remain potent assertion vehicles. The fact that a solo inventor-patentee successfully obtained Federal Circuit reversal against a major multinational device manufacturer underscores that patent quality and appellate advocacy can level the playing field.
3. Continuation portfolio strategies matter. Five patents from a single inventive lineage create redundancy and breadth — if one patent fails on claim construction, others in the family may still capture the accused product.

Industry & Competitive Implications

The spinal surgery device market — valued at tens of billions globally — is intensely competitive, with manufacturers like DePuy, Medtronic, NuVasive, and Globus Medical defending product platforms through both innovation and litigation. A Federal Circuit reversal in favor of an individual inventor asserting derotation technology patents sends a clear signal: foundational surgical method patents covering MIS correction techniques retain significant litigation value.

For DePuy, the remand creates continued litigation exposure for two commercially active product lines. Depending on the outcome below, licensing negotiations, design modifications, or ongoing litigation costs will factor into product strategy.

For the broader industry, this case reflects a growing trend of individual inventors and smaller entities successfully asserting medical device patents through specialized appellate counsel — a trend that R&D-heavy companies must monitor via active IP landscape surveillance. Companies launching new spinal correction platforms should commission thorough FTO analyses covering the Barry patent family before commercialization.